Barclays on U.S Medical Supplies and Devices: Weekly Insight and Observations (SYK, MDT)
Tweet
Share
E-mailGet Alerts SYK Hot Sheet
Price: $329.45 +0.53%
Rating Summary:
33 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
33 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays on U.S Medical Supplies and Devices: Weekly Insight and Observations
Analyst, Matthew Taylor started with a review of Stryker's (NYSE: SYK) analyst day. Saying there wasn't any big, breaking news, the place was well attended and some key themes included: 1) Capital Allocation - reaffirming comfort with current dividend, there were some M&A areas of interest and willingness to share buyback program; 2) Margin and Cash Flow Improvements - five year plan to focus on operating margins and cash flow optimization; 3) International - raising presence in under represented markets. Taylor keeps an Equalweight rating on shares, citing current valuation.
From Medtronic's (NYSE: MDT) 10-Q Filing: Taylor said there were no surprise disclosures from the filing, and no updates regarding the company's warning letter from the FDA regarding Neuromod. The letter may affect the launch, but MDT doesn't expect a material impact on financial results.
Analyst, Matthew Taylor started with a review of Stryker's (NYSE: SYK) analyst day. Saying there wasn't any big, breaking news, the place was well attended and some key themes included: 1) Capital Allocation - reaffirming comfort with current dividend, there were some M&A areas of interest and willingness to share buyback program; 2) Margin and Cash Flow Improvements - five year plan to focus on operating margins and cash flow optimization; 3) International - raising presence in under represented markets. Taylor keeps an Equalweight rating on shares, citing current valuation.
From Medtronic's (NYSE: MDT) 10-Q Filing: Taylor said there were no surprise disclosures from the filing, and no updates regarding the company's warning letter from the FDA regarding Neuromod. The letter may affect the launch, but MDT doesn't expect a material impact on financial results.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- UBS says bull market has further to run
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, Dividend, Stock Buyback, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
